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digital images of various areas of the tumor. Determinations of poten-
tial sensitivity or resistance was based on the relative level of compara-
tive IF expression and comparison with an in vitro ﬂuorescent reference 
standard. The criteria for resistance versus susceptible is established 
from the internal comparison for the in vitro studies. Within the eight 
lung cancer cell lines in culture, the comparatively resistant cells 
require 7-10 fold higher drug concentrations for the same cytotoxicity 
(IC50) than the comparatively susceptible cells. The expression levels 
of ERCC-1 and beta-tubulin III correlates well with these requirements 
of drug concentrations for same cytotoxicity (IC50 ) with a Pearson 
coefﬁcient of about 0.9. IF signals exceeding those of the most resistant 
and overexpressing line were considered resistant. Final characteriza-
tion of the tumor was based upon both the ERCC1 and BTUB staining. 
Specimens sensitive to both agents were characterized as sensitive (S), 
all others were considered resistant (R). Laboratory personnel were 
blinded to pt identity and outcomes.
Results: 47 pts were enrolled on the study between 1/2000 and 5/2004. 
All pts have completed therapy. The median overall survival is 29.6 
months and median event free survival is 16.9 months. Specimens 
from 10 pts have been analyzed. 4 were sensitive and 6 resistant. There 
was no difference in event free survival between the S and R groups. 
However, there was a trend (p=.08) towards improved overall survival 
in the S group.
Conclusions: 1. This IF assessement can be rapidly performed on 
parafﬁn blocks and provides a quantitative assessment of ERCC1 and 
BTUBB III expression that is not observer dependent. 2. These very 
preliminary data indicate that ERCC1 and BTUBB III may correlate 
with survival in Stage III NSCLC treated with CMT. Additional data 
will be available by the time of the meeting. 
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Background: ABT-751 is an orally bioavailable sulfonamide that binds 
to the colchicine site on β-tubulin and inhibits polymerization of micro-
tubules. Pemetrexed (Alimta®) is an antineoplastic agent that interrupts 
cell replication. Both compounds have been evaluated individually in 
advanced NSCLC subjects and in combination in preclinical xenograft 
models.
Methods: The Phase 1 open-label dose escalation portion of the 
study was designed to determine the maximum tolerated dose (MTD) 
and recommended Phase 2 dose (RPTD) of ABT-751 when adminis-
tered with pemetrexed. For each cycle, subjects received 500 mg/m2 
pemetrexed IV on Day 1 and ABT-751 orally QD for 14 consecutive 
days followed by 7 days off drug. Dose levels of ABT-751 began at 
200 mg and escalated in 50 mg increments. Pharmacokinetic sampling 
was performed on Day 1 of Cycle 1. The Phase 2 portion of the study 
was designed to determine the effect of ABT-751 plus pemetrexed on 
progression-free survival.
Results: Nine subjects have been accrued into the Phase 1 portion of 
the study. The MTD and RPTD were determined to be 200 mg of ABT-
751 QD for 14 days. Two of 6 subjects (33%) in the 250 mg cohort 
experienced a dose-limiting toxicity (DLT) (1 grade 3 [CTCAE version 
3.0] neuropathy; 1 grade 5 intestinal infarction, shown by CT scan to be 
consistent with ischemic infarction). Two additional subjects reported 
grade 3 treatment-emergent adverse events (fatigue [2], constipation 
[1], dyspnea [1]), which the investigator considered probably or pos-
sibly related to ABT-751. Preliminary pharmacokinetic results for ABT-
751 after the concomitant administration of ABT-751 and pemetrexed 
were comparable to those after the administration of ABT-751 alone 
in a previous Phase 1 study. Preliminary laboratory data for grade 3/4 
hematologic parameters indicate the incidence of neutropenia was 2/8 
(25%) and thrombocytopenia and anemia were each 0% for subjects 
receiving ABT-751 and pemetrexed. The incidences from the peme-
trexed label are 5% for neutropenia, 2% for thrombocytopenia, and 
8% for anemia. Two subjects had partial responses; 1 conﬁrmed and 1 
unconﬁrmed.
Pharmacokinetic parameters of ABT-751 after single oral dose of ABT-751
 
200 mg ABT-751 
With Pemetrexed
200 mg ABT-751 
Alone#
250 mg ABT-751 
With Pemetrexed##
250 mg ABT-751 
Alone#
N 3 23 5 3
Tmax (h) 0.8 ± 0.3 2.0 ± 1.3 3.2 ± 1.8 1.3 ± 0.6
Cmax (μg/mL) 9.9 ± 9.8 9.1 ± 4.5 8.2 ± 4.2 10.9 ± 3.3
AUC0-8 
(μg*h/mL) 27.2 ± 12.9 33.0 ± 10.1 34.9 ± 15.8 45.5 ± 10.5
#From a previous Phase 1 study M01-303
## One subject had unusually low drug plasma levels, which resulted iin lower means for Cmax and AUC0-8 
for the 250 mg dose.
Conclusions: Both the MTD and RPTD of the combination of ABT-
751 and pemetrexed have been determined. Coadministration of peme-
trexed with ABT-751 does not appear to affect the pharmacokinetic 
proﬁle of ABT-751.
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Background: Lung cancer is the leading cause of cancer related death 
worldwide in both males and females. Despite the poor prognosis of 
patients with advanced NCSLC, treatment with the new generation che-
motherapy agents has improved survival, quality of life and decreased 
toxicity compared to older regimens.
Methods: In this study, patients were randomly assigned to receive 
either paclitaxel 175mg/m2 (day1) or gemcitabine 1,250mg/m2 (days 
1 and 8) both combined with cisplatin 80mg/m2 (day 1) or paclitaxel 
175mg/m2 (day1) combined with gemcitabine 1,250 mg/m2 (days 1 
and 8) as ﬁrst line therapy for stage III b having pleural effusion or 
supraclavicular lymph node metastasis and stage IV NSCLC. Primary 
endpoint was comparison of overall survival for the 3 arms. Secondary 
endpoints included response rate, progression free survival and toxici-
ties.
Results: Sixty two patients (arm A, 19, arm B 23, arm C 20 patients) 
were enrolled. Major clinical characteristics in arm A/B/C were: 
Median age 51, 50, and 47 years, stage IV 14 %, 13 %, and 16 %, 
